Scripps Research's banner
Scripps Research's profile picture

Scripps Research

@scrippsresearch • 279,360 subscribers

Scripps Research is one of the world's largest, private, non-profit biomedical research organizations. We are Science Changing Life.

Shorts

Meet the next-generation approach to cancer treatment. 💊🌟 Switchable CAR-T (sCAR-T) is a programmable immunotherapy designed to give scientists and clinicians greater control over how—and when—the immune system attacks cancer. This modular CAR-T platform activates engineered immune cells only in the presence of an antibody “switch.” Without the switch, the cells remain inactive, an approach designed to improve precision and lifespan, while potentially reducing the risk of uncontrolled immune responses. Scientists at Scripps Research’s drug development division, Calibr-Skaggs Institute for Innovative Medicines, have completed a Phase 1 clinical trial evaluating the safety of the sCAR-T platform (CLBR001) paired with a CD19-targeted switch (SWI019) for B-cell malignancies (NCT04450069). Initial results announced underscore the potential of this therapy. The technology is now being tested in a Phase 1 clinical trial for metastatic breast cancer, with an additional Phase 1 trial for autoimmune diseases launching this year. #WorldCancerDay #CancerResearch #Immunotherapy #BreastCancerResearch #ClinicalTrials

Meet the next-generation approach to cancer treatment. 💊🌟 Switchable CAR-T (sCAR-T) is a programmable immunotherapy designed to give scientists and clinicians greater control over how—and when—the immune system attacks cancer. This modular CAR-T platform activates engineered immune cells only in the presence of an antibody “switch.” Without the switch, the cells remain inactive, an approach designed to improve precision and lifespan, while potentially reducing the risk of uncontrolled immune responses. Scientists at Scripps Research’s drug development division, Calibr-Skaggs Institute for Innovative Medicines, have completed a Phase 1 clinical trial evaluating the safety of the sCAR-T platform (CLBR001) paired with a CD19-targeted switch (SWI019) for B-cell malignancies (NCT04450069). Initial results announced underscore the potential of this therapy. The technology is now being tested in a Phase 1 clinical trial for metastatic breast cancer, with an additional Phase 1 trial for autoimmune diseases launching this year. #WorldCancerDay #CancerResearch #Immunotherapy #BreastCancerResearch #ClinicalTrials

17,254 views

Videos

LIVE
1.2k

Anya Rossi

sweetdream.ai

SweetDream.aiSponsored•Livecam
Streaming Now

Watch Anya Live

Anya is streaming live right now! Join her private show and enjoy exclusive content.

HD live stream
Exclusive private shows
1.2k viewers online

Free preview available • Premium content

Meet Alexandra Salazar, a PhD Candidate at #ScrippsResearch. 👋 She works in the Lander Lab, where researchers use data collection and image processing strategies to understand what goes wrong with the molecular machinery in cells during various disease states.
0:59
scrippsresearch's profile picture

Meet Alexandra Salazar, a PhD Candidate at #ScrippsResearch. 👋 She works in the Lander Lab, where researchers use data collection and image processing strategies to understand what goes wrong with the molecular machinery in cells during various disease states.

Scripps Research

19,787 views • 2 years ago

No more content to load